APO-DASATINIB DIN 02470705
Health Canada record
| Active ingredient(s) | DASATINIB 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EA02 DASATINIB |
| Original market date | 06-Jan-2020 |
| Current status date | 06-Jan-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DASATINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02470713 | APO-DASATINIB | APOTEX INC | Tablet | DASATINIB 50 MG | Marketed |
| 02470721 | APO-DASATINIB | APOTEX INC | Tablet | DASATINIB 100 MG | Marketed |
| 02481499 | APO-DASATINIB | APOTEX INC | Tablet | DASATINIB 70 MG | Marketed |
| 02481502 | APO-DASATINIB | APOTEX INC | Tablet | DASATINIB 80 MG | Marketed |
| 02499282 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 20 MG | Marketed |
| 02499304 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 50 MG | Marketed |
| 02499312 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 70 MG | Marketed |
| 02499320 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 80 MG | Marketed |
| 02499339 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 100 MG | Marketed |
| 02499347 | TARO-DASATINIB | TARO PHARMACEUTICALS INC | Tablet | DASATINIB 140 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22961 | 2019-11-28 | Abbreviated New Drug Submission (ANDS) |
International API supply for DASATINIB
30 active FDA Drug Master Files.
Request a quote for APO-DASATINIB